Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 6Gastro-enteropancreatic neuroendocrine tumor 3Carcinoid Tumor 2Prostatic Neoplasms 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Liver Neoplasms 1Hypoglycemia 1Dumping Syndrome 1Carcinoma 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

Everolimus 3tislelizumab 1surufatinib 1romidepsin 1regorafenib 1pembrolizumab 1pasireotide 1lutetium Lu 177 dotatate 1folfirinox 1fludarabine phosphate 1epothilone B 1cixutumumab 1Surgical Procedures, Operative 1Sunitinib 1Specimen Handling 1Radiosurgery 1Octreotide 1Magnetic Resonance Spectroscopy 1Liver Transplantation 1Lactones 1LY2584702 1Interleukin-13 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Erlotinib Hydrochloride 1Embolization, Therapeutic 1Doxorubicin 1Depsipeptides 1Cytokines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × pasireotide × NET × Clear all
NCT01253161 2023-03-06

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
29 enrolled 11 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡